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Abstract 1 
Resistance to the innate defences of the intestine is crucial for the survival and 2 
carriage of Staphylococcus aureus, a common coloniser of the human gut.  Bile salts 3 
produced by the liver and secreted into the intestines are one such group of molecules 4 
with potent anti-microbial activity.  The mechanisms by which S. aureus is able to 5 
resist such defences in order to colonize and survive in the human gut are unknown.  6 
Here we show that mnhF confers resistance to bile salts, which can be abrogated by 7 
efflux pump inhibitors.  MnhF mediates efflux of radiolabelled cholic acid in both S. 8 
aureus and when heterologously expressed in Escherichia coli, rendering them 9 
resistant.  Deletion of mnhF attenuated survival of S. aureus in an anaerobic three-10 
stage continuous culture model of the human colon (gut model), which represent 11 
different anatomical areas of the large intestine.  12 
 3 
Introduction 13 
Staphylococcus aureus is a ubiquitous and highly adaptable human pathogen 14 
responsible for a significant global burden of morbidity and mortality.  The bacterium 15 
lives as a commensal in the nares of 20-25% of the population at any one time (1, 2).  16 
While nasal colonisation is a well-established risk factor for most types of S. aureus 17 
infections, several recent studies have suggested that colonisation of the intestine, 18 
which occurs in c. 20% of individuals and which by and large has been overlooked, 19 
could have important clinical implications (3).  Patients with S. aureus intestinal 20 
colonisation can serve as an important source of transmission, as they often 21 
contaminate the adjacent environment (4).  Similarly, such patients display an 22 
increased frequency of skin colonisation (5).  A study in intensive care and liver 23 
transplant units showed that patients with both rectal and nares colonisation by MRSA 24 
had a significantly higher risk of disease (40%) than did patients with nasal 25 
colonisation alone (18%) (6).  Furthermore, a study of hospitalised patients in the 26 
United States reported co-colonisation by S. aureus and vancomycin-resistant 27 
enterococci in >50% of the individuals studied (7).  Thus it is likely that intestinal 28 
colonisation by S. aureus provides the pathogen with a potential opportunity to 29 
acquire new antibiotic resistance genes. 30 
 31 
While the clinical implications of intestinal colonisation by S. aureus are still 32 
relatively ill-defined, it is assumed that carriage is a risk for intestinal infection; S. 33 
aureus can induce pseudomembranous colitis that is histologically distinct from that 34 
caused by Clostridium difficile (8).  Multiple studies have demonstrated frequent 35 
intestinal colonisation in infants, particularly in those that were breast-fed and that a 36 
positive correlation exists with development of allergies (9-13).  While a role for S. 37 
 4 
aureus intestinal carriage in development of systemic S. aureus disease has not been 38 
established, colonisation of the intestinal lumen of mice can lead to the pathogen 39 
crossing the intestinal epithelial barrier and subsequent spread to the mesenteric 40 
lymph nodes (14, 15). 41 
 42 
As a common commensal and pathogen, S. aureus must resist the human host’s innate 43 
defences that have evolved to limit its in vivo growth and spread.  In particular, bile 44 
represents a major challenge to bacteria that survive transit through the stomach and 45 
enter the intestines.  Bile is a digestive secretion that plays an essential role in 46 
emulsification and solubilisation of lipids.  We have previously demonstrated survival 47 
of S. aureus in a human colonic model fed with physiological levels of bile (16).  48 
Resistance to bile salts has been demonstrated to be important for intestinal survival 49 
of several enteric pathogens, but in S. aureus such an understanding is lacking.  The 50 
role of the S. aureus mnhABCDEFG locus in bile resistance was identified using a 51 
Tn917 library screened for bile-sensitive mutants.  MnhF is homologous to 52 
mammalian bile salt transporters, thus we hypothesized that it was involved in bile 53 
resistance and therefore survival of S. aureus in conditions modeling the human 54 
colon.   55 
 56 
Here we provide molecular proof that a cause of bile salt resistance in S. aureus is 57 
efflux, catalysed by MnhF.  This represents the first description of an intestinal 58 
colonisation factor in this pathogen. 59 
 60 
 61 
 62 
 5 
Materials and Methods 63 
Bacteria, plasmids and growth conditions 64 
The strains and plasmids used in this work are listed in Tables 1 and 2, respectively.  65 
Escherichia coli strains were grown on Luria–Bertani medium, using selection with 66 
the antibiotic ampicillin (100 µg/mL) where appropriate.  S. aureus was grown on 67 
Brain Heart Infusion (BHI) (Oxoid) at 37°C.  Where appropriate, antibiotics were 68 
added at the following concentrations: erythromycin 5 µg/mL, lincomycin 25 µg/mL.  69 
Phage transducions were as described previously (23). 70 
 71 
Determination of minimum inhibitory concentration (MIC) 72 
The MICs of selected bile salts, sodium cholate (CA), sodium chenodeoxycholate 73 
(CDCA), sodium deoxycholate (DCA), sodium glycocholate (GCA), and sodium 74 
taurocholate (TCA) were determined by broth dilution.  MICs were determined by 75 
doubling dilutions and MICs were reproduced in 3 independent experiments. 76 
 77 
Time-course measurement of bacterial viability upon exposure to bile salts. 78 
Overnight cultures were grown to mid-exponential phase in BHI broth at 37°C with 79 
shaking.  After harvesting, cells were washed twice with sterile 5 mM HEPES buffer 80 
(pH 7.2) containing 10 mM glucose, then resuspended in the same buffer to an OD600 81 
0.5. Cells were incubated with various concentrations of bile salt for 30 minutes at 82 
37°C.  At 10 minute intervals, dilutions from each of the bile salt treated groups were 83 
made with sterile peptone saline diluent. Dilutions were plated onto tryptic soy agar 84 
plates and incubated for overnight at 37°C.  Colonies were counted, and percentage 85 
viabilities calculated based on the initial untreated cell suspension. 86 
 87 
 6 
Generation of an in-frame mnhF mutant.  88 
For the ∆mnhF, DNA fragments corresponding to c. 0.7 kb upstream and downstream of 89 
mnhF were amplified using Pwo polymerase (Roche) with primers 90 
∆mnhFLFor/∆mnhFLRev and ∆mnhFRFor/∆mnhFRRev (Table 3). Following 91 
purification, PCR products were digested with BamHI/EcoRI and cloned into pMAD.  92 
The resulting plasmid was used to transform electrocompetent S. aureus RN4220 (24).   93 
Plasmids were transduced into SH1000 using φ11 phage. The temperature sensitive 94 
nature of plasmid replication was exploited to integrate the plasmid into the bacterial 95 
chromosome, by plating cells on media containing erythromycin and lincomycin at 42ºC. 96 
After further rounds of plating, erythromycin and lincomycin sensitive colonies were 97 
isolated and the loss of mnhF confirmed by PCR. 98 
 99 
Cloning and expression of mnhF.  100 
The mnhF gene was amplified by PCR with S. aureus SH1000 DNA.  For cloning into S. 101 
aureus, mnhFFor2 and mnhFRev (Table 3) were used.  PCR products were digested with 102 
EcoRI and BamHI and ligated into similarly digested pRMC2.  This created pMnhF2, 103 
where mnhF is fused to Pxyl/tetO, which is under the control of TetR and induced with 104 
anydrotetracycline.    For cloning into E. coli, oligonucleotides mnhFFor1 and mnhFRev 105 
(Table 3) were used.  PCR products were digested with EcoRI and BspHI and ligated into 106 
similarly digested pBAD/His A.  This created pMnhF1, where mnhF is fused to PBAD, 107 
which is under tight control of AraC.   108 
 109 
Bile salt accumulation assay.   110 
Accumulation of cholic acid in S. aureus was quantified using a previously described 111 
method (25).  Briefly, S. aureus and E. coli were grown in BHI and LB broth 112 
respectively, at 37°C to an OD600 c. 0.6.  Cells were centrifuged (5 mins, 16,000g), 113 
 7 
washed twice in 25mM potassium phosphate buffer (pH 7.0) containing 1mM MgSO4 114 
and resuspended in same buffer to a concentration of 100 OD units/mL.  One µCi of 115 
14C labelled cholic acid (American Radiolabelled Chemicals) with specific 116 
radioactivity of 55 mCi/mmol was added, to a final concentration of 18 µM, cells 117 
were incubated at 37°C for 2 h.  Cells were then diluted to 10 OD units/ml in 25 mM 118 
potassium phosphate buffer (pH 7.0) containing 1 mM MgSO4, 20 mM glucose and 119 
0.2 mM non-radiolabelled cholic acid, and incubated at 37°C.  Incorporation of 120 
radiolabelled cholic acid was measured by scintillation counting.  At the indicated 121 
time, 250 µl cells were centrifuged at 16,000g for 2 min, and the pellets resuspended 122 
in 500 µl of sterile water and 3 ml of Ulitma Gold scintillation cocktail (Perkin 123 
Elmer).  CPM were counted in a Beckman LS 6500 Coulter liquid scintillation 124 
counter.   125 
 126 
Quantitative real-time PCR. 127 
mRNAs from mutant and wild type strains were quantified using quantitative real-128 
time PCR (qRT-PCR).  Cells were grown in triplicate as described above, then treated 129 
with RNA protect (Qiagen) and RNA was isolated using the Qiagen RNeasy Mini kit.  130 
DNA was removed using Turbo DNase-free (Life Technologies).  Purified RNA was 131 
quantified using a nonodrop ND-1000 spectrophotometer (Thermo Scientific).  0.5 µg 132 
of RNA was reverse transcribed using the Tetro cDNA synthesis kit (Bioline).  qRT-133 
PCR was performed using the Aligent qPCR System and iQ SYBR Green Supermix 134 
(Biorad).  The relative amounts of RNAIII mRNA in parental wild type and mutant 135 
cells was determined by relative quantification using gyrB, based on consistent levels 136 
observed in previous studies (26, 27, 28, 29).   The oligonucleotides used for qRT-137 
PCR are listed in Table 3. 138 
 8 
 139 
Three-stage continuous culture colonic model system (human gut model). 140 
The three-stage continuous culture model of the human colon has been described 141 
previously (16, 30).  The experiment was carried out in triplicate using faecal samples 142 
from three different volunteers.  After obtaining verbal informed consent, a standard 143 
questionnaire to collect information regarding the health status, drugs use, clinical 144 
anamnesis, and lifestyle was administrated before the donor was ask to provide a 145 
faecal sample.  No volunteers had received antibiotics, probiotics, steroids or other 146 
drugs with a proven impact on gut microbiota for at least 3 months before sampling.  147 
None of them had any history of gastrointestinal disorder.  All healthy faecal donors 148 
had the experimental procedure explained to them and were given the opportunity to 149 
ask questions. The University of Reading research Ethics Committee exempted this 150 
study from review because no donors were involved in any intervention and waived 151 
the need for written consent due to the fact the samples received were not collected by 152 
means of intervention. All faecal samples were collected on site, kept in an anaerobic 153 
cabinet (10 % H2, 10 % CO2 and 80 % N2) and used within a maximum of 15 minutes 154 
after collection. Samples were diluted 1/10 w/v in anaerobic PBS (0.1 mol/l phosphate 155 
buffer solution, pH 7.4) and homogenized (Stomacher 400, Seward, West Sussex, 156 
UK) for 2 minutes at 460 paddle-beats.   157 
 158 
Samples were plated onto BHI agar containing 0.01% (w/v) potassium tellurite as a 159 
selective agent at different dilutions in PBS (from 102 to 109 CFU/ml) in triplicate for 160 
each time point to measure bacterial counts.   161 
 162 
 9 
Statistical analysis 163 
All experiments were repeated three times and data were presented as ± standard error 164 
of mean.  Analysis was performed using GraphPad Prism 5 software.  Experimental 165 
data were analysed by One-Way Anova and Two-Way Anova method, using 166 
Bonferroni post-test analysis. 167 
 168 
Results 169 
Identification of a bile salt resistance locus. 170 
Genes conferring resistance to bile were identified by replica plating S. aureus 171 
SH1000 Tn917 insertion libraries on BHI agar and onto BHI agar containing 18% 172 
(w/v) bile salts (Oxoid), which represented 0.8 Í MIC.  Six colonies were unable to 173 
grow in the presence of bile salts, but exhibited no growth defect on BHI agar in the 174 
absence of bile.  Sequencing of the genomic DNA flanking the transposon insertion 175 
site of bile sensitive strains was carried out in order to identify the DNA insertion 176 
sites of Tn917, revealing that all six strains were siblings containing the transposon 177 
inserted in the same gene, namely the previously described mnhA, the first gene in the 178 
polycistronic mnhABCDEFG operon which encodes a Na+/H+ antiporter (31).  179 
Bacillus subtilis contains the orthologous mrpABCDEFG operon that has an identical 180 
function, however mrpF and by extension mnhF, are homologous to mammalian bile 181 
transporters and mrpF mediates cholic acid efflux (32, 33).  182 
 183 
MnhF mediates resistance to bile salts. 184 
We hypothesized that MnhF was responsible for the observed bile salt resistance 185 
phenotype.  To test this, an in-frame ∆mnhF strain was created in S. aureus SH1000.  186 
The mutant strain had no growth defect when grown on BHI solid or liquid media in 187 
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the absence of bile salts (results not shown).  Compared to the parental wild type, the 188 
∆mnhF strain had a reduced MIC for unconjugated bile salts and, in particular, cholic 189 
acid (Table 4).  Complementation of mutation with mnhF under the control of an 190 
inducible promoter restored the bile resistance phenotype to that observed in the 191 
parent strain in the presence of anhydrotetracycline as an inducer (Table 4), whereas 192 
there was no such resistance in the absence of the inducer (results not shown).  In 193 
killing assays, the ∆mnhF strain was significantly more sensitive than the parent.  In 194 
the presence of 1 µg/mL anhydrotetracycline, the complemented strain exhibited a 195 
similar rate of cell death as the parental wild type (Fig 1).  The increased sensitivity of 196 
the mutant strain was only observed with unconjugated bile salts. However it should 197 
be noted that we were unable to determine the MIC of conjugated bile salts for S. 198 
aureus, as they were insoluble at concentrations greater than 200 mM. 199 
 200 
To confirm the role of mnhF in bile salt resistance, it was cloned under the control of 201 
the arabinose-inducible PBAD promoter of plasmid pBAD/HisA, which enabled 202 
arabinose-dose dependent expression of MnhF in E. coli TG1 and TOP10 strains.  203 
Expression of MnhF increased the MICs to both conjugated and unconjugated bile 204 
salts in both background strains and in the case of cholic acid, the increased resistance 205 
was arabinose-dose dependent (Table 5).  Similarly, expression of MnhF in E. coli 206 
decreased the bacteriostatic effects of bile salts on that bacterium (Fig 2).  Thus MnhF 207 
was sufficient to enable bile salt resistance in the absence of the rest of the 208 
mnhABCDEFG operon.   209 
 210 
The effect of efflux pump inhibitors on bile salt resistance. 211 
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Given the ability of MnhF to confer bile salt resistance and its similarity to other 212 
known and putative bile efflux systems, its ability to mediate removal of cholic acid 213 
from bacteria was tested.  Both Phe-Arg-β-naphthylamide (PAβN), a synthetic 214 
dipeptide that inhibits bacterial efflux pumps, including bile salt efflux pumps of 215 
Gram negative bacteria, and reserpine, a plant alkaloid which can inhibit multidrug 216 
efflux pumps in Gram positive bacteria, were tested for their ability to reduce bile salt 217 
MICs in S. aureus.  Both inhibitors caused reductions in the S. aureus MIC for cholic 218 
acid and PAβN reduced the MIC for all three unconjugaged bile salts (Table 6A), 219 
however the reduction was much smaller in the ∆mnhF strain than the parental wild-220 
type, possibly indicating the presence of other bile salt efflux systems in the pathogen.  221 
Similarly, in E. coli (pMnhF1), PAβN reduced bile salt MICs to levels lower than that 222 
for untreated E. coli (pBAD His A) (Table 6B).  Thus in both S. aureus and E. coli, 223 
inhibitors of efflux pumps abrogated bile salt resistance in an MnhF dependent 224 
manner. 225 
 226 
MnhF transports cholic acid. 227 
Given the ability of efflux pump inhibitors to reduce the MICs of certain bile salts in 228 
S. aureus, the capacity of the MnhF to transport cholic acid was determined in 229 
vitro using a 14C-radiolabelled cholic acid substrate, similar to previous efflux assays 230 
(25, 34, 35).  S. aureus SH1000 and ∆mnhF strains were incubated with 14C-cholic 231 
acid (uptake period) and then diluted in buffer containing excess of non-radiolabelled 232 
cholic acid (efflux period).  Initial 14C-cholic acid uptake was the same for both 233 
strains (10962 ± 550 cpm for S. aureus SH1000 and 10278 ± 278 cpm for S. aureus 234 
∆mnhF), but throughout the efflux period S. aureus ∆mnhF retained significantly 235 
more of the radiolabel than the parental wild-type (Fig 3A).  To further corroborate 236 
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these findings, efflux assays were also carried out on E. coli expressing MnhF.  E. coli 237 
TG1, E. coli TG1 (pBAD) and E. coli TG1 (pMnhF1) were grown overnight in LB 238 
supplemented with 1% arabinose at 37°C, then incubated with 14C- cholic acid.  All 239 
the E. coli TG1 strains incorporated similar levels of 14C-cholic acid during uptake 240 
period (20774 ± 363 for TG1, 23274 ± 386 for TG1: pBAD and 22435 ± 460 CPM 241 
for TG1: pMnhF1).  At various points after the initial incorporation of radiolabelled 242 
cholic acid, cells were centrifuged and cell-associated radioactivity was determined 243 
by liquid scintillation method.  E. coli TG1 cells expressing MnhF retained 244 
significantly (P<0.05) lower levels of 14C-radiolabelled cholic acid than parental TG1 245 
and TG1 cells with the empty pBAD vector (TG1: pBAD) (Fig 3B).  In both sets of 246 
experiments the reason for increasing cell-associated radiolabel during the efflux 247 
period, after which cells have been diluted in excess non-labelled cholic acid, is 248 
unclear, but has also been observed in previous studies on Listeria monocytogenes 249 
and may reflect continued incorporation of 14C-cholic acid during the efflux period 250 
after dilution (25).  251 
 252 
Bile salt resistance is not affected by agr. 253 
To examine whether agr quorum sensing system is involved in bile salt resistance, the 254 
MICs for CA, DCA and CDCA in S. aureus SH1001 (agr) were determined and 255 
found to be indistinguishable from those of the wild type (results not shown).  256 
Furthermore, the agr system is not inhibited by the mnhF mutation as the RNAIII 257 
effector molecule is still produced (Fig 4).  Thus we were unable to demonstrate a role 258 
for agr in bile resistance. 259 
 260 
MnhF is required for survival of S. aureus in a human gut model. 261 
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To examine the role of MnhF in survival of S. aureus in conditions found in the 262 
human colon, we used a three-stage continuous culture gut model system, designed to 263 
reproduce the spatial, temporal, nutritional and physicochemical characteristics of the 264 
microbiota in the human colon.  In vivo studies of colonic bacteria are hampered by 265 
the lack of suitable animal models, as these do not correctly simulate the microbiota 266 
and physicochemical conditions of the human colon (36).  We have previously used 267 
this in vitro model to study survival of S. aureus and the impact of infection on the 268 
host’s intestinal microflora (16). 269 
 270 
Mutational inactivation of the whole mnhABCDEFG operon does not affect the ability 271 
of S. aureus to grow at a range of pH levels (37).  In order to exclude the possibility 272 
that the normal pH range (5.5 to 7.5) found in the colon, influenced survival of the 273 
∆mnhF mutant, we corroborated the previous observation at pH 5.5 to 8.5 using this 274 
strain (results not shown).   275 
 276 
After inoculating vessel 1 (which models the proximal colon) of the colonic models 277 
with S. aureus to a concentration of c. 2×1010 cfu/mL, as a single dose, the S. aureus 278 
populations stabilised at 6 to 7 Log10 units over a period of up to 8 hours.  Survival of  279 
S. aureus ∆mnhF was significantly attenuated compared to its parental strain in all 280 
three vesels (Fig 5A-C). 281 
 282 
Discussion 283 
A complex set of interactions exists between S. aureus and its human host as the 284 
bacterium is able to colonize several niches, both as an opportunist pathogen of great 285 
medical importance and as a common commensal.  In order to defend against 286 
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colonization by microorganisms, the host produces a range of antimicrobials such as 287 
peptides, fatty acids and bile.  Bile represents one significant challenge to the gut 288 
microflora; in humans the liver secretes up to one liter of bile per day into the 289 
intestines (38).  Furthermore molecules secreted by bacteria, including S. aureus, 290 
during infection are an important cause of metabolic cholestasis; an inability of 291 
hepatocytes to produce bile (39).  Bile is a complex cocktail composed principally of 292 
bile salts, phospholipids, cholesterol, proteins and bilirubin (40).  Originally 293 
characterised as digestive molecules, bile salts have antimicrobial activity, which has 294 
been attributed to their ability to damage cell membranes (41).  Additionally, they 295 
cause intracellular acidification, induce formation of secondary structures in RNA, 296 
DNA damage and misfolding and denaturation of proteins.  Thus bile salts represent a 297 
serious challenge to bacterial cells in the gastrointestinal tract and bacteria that are 298 
able to colonise the gut should therefore be able to overcome their toxicity. 299 
 300 
Bile salts which pass into the large intestine undergo modification by the normal 301 
microbiota  (42).  The major modifications include deconjugation, oxidation of 302 
hydroxyl groups ant C-3, C-7 and C-12, and 7α/β-dehydroxylation (43, 44).  Thus the 303 
normal commensal inhabitants of the human gastrointestinal tract such as 304 
Lactobacillus, Propionibacterium and Bifodobacterium, are required by the host for 305 
maintenance of gut health and the ecological balance by influencing the composition 306 
of the bile acids in the large intestine and by extension, the gut microbiome (45, 46).  307 
Their ability to survive in the presence of bile salts indicates the existence of inherent 308 
bile resistance mechanisms.  Indeed, colonic commensals deploy various different 309 
strategies for resisting bile.  Lactobacillus plantarum produces a bile salt hydrolase, 310 
which detoxifies bile salts by deconjugating bile salts inside the cell, turning them into 311 
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weaker acids, thus negating the drop in pH that they cause (47).  Bifidobacteria 312 
possess a number of characterised bile salt resistance mechanisms.  In addition to 313 
multiple efflux pumps, exposure to bile salts results in a modification of the cell 314 
envelope.  Increased concentrations of membrane fatty acids and altered 315 
phospholipids increase membrane rigidity and reduce the permeability to lipophilic 316 
bile salts (48).  Similarly, exposure of Bifidobacterium animalis ssp lactis to bile salts 317 
induces increased expression of exopolysaccharides, which are proposed to form a 318 
protective layer around the bacterium (49). 319 
 320 
Bile salts represent a physiological challenge for bacteria and an environmental cue; 321 
Salmonella enterica and Vibrio cholera regulate intestinal colonisation and virulence 322 
in response to bile (50, 51).  However pathogens that inhabit the human intestines are 323 
also exposed to the bactericidal nature of bile salts and hence must also exhibit 324 
resistance in order to survive.    Generally, Gram-negative bacteria are more innately 325 
resistant than Gram positives, due to the presence of an outer membrane, which acts 326 
as a barrier (38).  Indeed maintenance of membrane integrity by lipopolysaccharide 327 
(LPS) in the cellular envelope of Gram-negative bacteria imparts protection against 328 
the actions of bile salts (52, 53).    Salmonella typhi and Salmonella typhimurium are 329 
able to grow at bile concentrations that are much higher than those encountered in 330 
vivo.  This is due, at least in part, to the presence of outer membrane efflux pumps 331 
such as AcrAB (54).  Similarly, HefC is an AcrB homologue that confers bile salt 332 
resistance in Helicobacter pylori (55).  The multidrug efflux pump CmeABC, of 333 
Campylobacter jejuni mediates bile salt resistance and is required for colonisation of 334 
chickens (56). Gram-positive pathogens such as Enterococcus faecalis and L. 335 
monocytogenes also exhibit bile resistance.  In addition to bile salt hydrolase 336 
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activities, both bacteria possess multiple bile efflux systems.  Exposure of E. faecalis 337 
to bile results in up-regulation of two open reading frames EF0420 and EF1814, 338 
which are homologous to the QacA family of efflux pumps (57). L. monocytogenes 339 
OpuC, an osmolyte transporter, as well as specialist bile transporters BilE and MdrT, 340 
all confer bile salt resistance to the pathogen (58).   341 
 342 
We demonstrated that the mnhABCDEFG operon in S. aureus confers bile salt 343 
resistance to the pathogen.  Previous studies have shown this operon to encode a 344 
multi-subunit hetero-oligomeric antiporter system involved in efflux of monovalent 345 
cations such as Na+, K+ and Li+ in exchange for H+ (59).  Transposon insertion into 346 
mnhD (also called snoD) resulted in reduced susceptibility to platelet microbicidal 347 
protein 1 (37), thus the operon also has the ability to sensitize the pathogen to other 348 
host innate antimicrobials.  The function of individual components remains to be 349 
determined, however mnhF is homologous to a hamster ileal bile salt transporter (60) 350 
and rat liver organic anion transporter that was shown to efflux cholic acid (61).  A 351 
transposon insertion at mnhA, which presumably had a polar effect on the rest of the 352 
operon and in-frame deletion of mnhF, rendered the bacterium equally susceptible to 353 
bile salts. Together with our observation that cloning of mnhF in E. coli increased the 354 
bile salt MIC, demonstrated that MnhF alone is sufficient to confer bile salt 355 
resistance.  Furthermore, MnhF acted to exclude cholic acid from both S. aureus and 356 
E. coli.   357 
 358 
In order to confirm that this increase sensitivity of S. aureus translated into a 359 
decreased ability of S. aureus to survive under conditions found in the human colon, 360 
we studied survival of the mutant in a well characterised in vitro three-stage system 361 
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which models the microbial and physicochemical conditions of the in the proximal, 362 
transverse and distal colon (30).  The ∆mnhF strain was attenuated in its ability to 363 
survive in the model, compared to the parental wild type.  To date, no suitable in 364 
vivo models have been developed to study carriage and survival of S. aureus in the 365 
human intestine.  Laboratory mouse models of infection do not reproduce the 366 
complex microbial ecosystem or the human gut’s physicochemical defences (36).  367 
 368 
The physiology of S. aureus in the human gut is very poorly understood, relative to 369 
other niches.  A recent study to determine S. aureus genetic traits associated with 370 
observed higher rectal carriage rates was inconclusive (62), thus this is the first report 371 
of an S. aureus intestinal colonisation factor.  Given the complex nature of the gut as a 372 
niche, it seems highly likely that other loci are similarly required.  Indeed it would 373 
appear from our data that other bile resistance factors also exist.  As such much 374 
remains to be discovered about the behaviour and survival of S. aureus in the human 375 
gut. 376 
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Table 1. Bacterial strains  631 
Strain Description/Genotype Source or  
Reference 
S. aureus SH1000 
S. aureus SH1001 
Wild type 
agr mutation in SH1000 
(17) 
(17) 
S. aureus RN4220 
S. aureus mnhA::Tn917 
Accepts E. coli DNA 
Tn917 inserted into mnhA in SH1000 
(18) 
This study 
S. aureus ∆mnhF ∆mnhF mutation in SH1000 This study 
E. coli Top10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 
araD139 Δ(ara-leu)7697 galE15 
galK16 rpsL(StrR) endA1 λ- 
 
Invitrogen 
E. coli TG1 F' [traD36 proAB+ lacIq lacZΔM15] 
supE thi-1 Δ(lac-proAB) Δ(mcrB-
hsdSM)5, (rK-mK-) 
 
Lucigen 
 632 
  633 
 29 
Table 2. Plasmids 634 
 635 
 636 
  637 
Plasmid name Description Antibiotic 
resistance 
Source or 
Reference 
pLTV1 
pMAD 
Carries Tn917 
Temperature sensitive (30°C) E. 
coli – S. aureus shuttle vector.  
pE194ts::pBR322 
EmR/TcR 
EmR 
(19) 
(20) 
pBAD His A Expression vector containing 
araBAD promoter 
ApR (21) 
pRMC2 S. aureus expression vector ApR/CmR (22) 
p∆mnhF Vector for ∆mnhF mutation EmR This study 
pMnhF1 pBAD His A containing mnhF 
internal fragment 
ApR This study 
pMnhF2 pRMC2 containing mnhF internal 
fragment 
ApR/CmR This study 
 30 
Table 3.  Oligonucleotides.   Restriction endonuclease sites are underlined 638 
Name Sequence 5'-3' 
∆mnhFLFor CCAAAAGGATCCGATCTTAATAAC 
∆mnhFLRev CATTAGAATTCATTATATTTCGCCCACC 
∆mnhFRFor TATGGAATTCGGTAAGGTGATTGAAC 
∆mnhFRRev GCGATTGCGGATCCCTGTATGCC 
mnhFFor1 GGGCGAAATATCATGAATCATAATG 
mnhFFor2 GGGCGAAATAGGATCCATCATAATG 
mnhFRev TGATGAATTCGATAAGTGCAAGACTAATC 
RNAIIIFor ACATGGTTATTAAGTTGGGATGG 
RNAIIIRev TAAAATGGATTATCGACACAGTGA 
gyrBFor ATCGACTTCAGAGAGAGGTTTG 
gyrBRev CCGTTATCCGTTACTTTAATCCA 
 639 
 640 
 641 
 642 
  643 
 31 
Table 4.  MICs of bile salts for S. aureus SH1000 and ∆mnhF 644 
Bile salt Wild type 
 (mM) 
∆mnhF 
 (mM) 
∆mnhF  [pMnhF2] 
(mM) 
∆mnhF  [pRMC2] 
(mM) 
CA 22 5 22 5 
DCA 1.2 0.6 1.2 0.6 
CDCA 1.2 0.6 1.2 0.6 
GCA >200 >200 ND ND 
TCA >200 >200 ND ND 
 645 
NOTE.  CA, sodium cholate; DCA, sodium deoxycholate; CDCA, sodium 646 
chenodeoxycholate; GCA, sodium glycocholate; TCA, sodium taurocholate.  ND, not 647 
determined. 648 
 649 
 650 
 651 
 652 
 653 
 654 
 655 
 656 
 657 
 658 
 659 
 660 
  661 
 32 
Table 5.  MICs of bile salts for wild type and recombinant E. coli strains 662 
expressing MnhF at different levels of arabinose induction 663 
 664 
NOTE.  CA, sodium cholate; DCA, sodium deoxycholate; CDCA, sodium 665 
chenodeoxycholate; GCA, sodium glycocholate; TCA, sodium taurocholate. 666 
 667 
 668 
 669 
 670 
 671 
 672 
  673 
Bile 
salt 
Wild type Vector control Recombinants 
 TG1 TOP10 TG1 
pBAD 
TOP10 
pBAD 
TG1 pMnhF1 TOP10 pMnhF1 
     0% 
Arabinose 
0.02% 
Arabinose 
2% 
Arabinose 
0% 
Arabinose 
0.02% 
Arabinose 
2% 
Arabinose 
CA 30 30 30 30 30 60 90 30 60 90 
DCA 4 4 4 4 4 >4 >4 4 >4 >4 
CDCA 4 4 4 4 4 >4 >4 4 >4 >4 
GCA 50 50 50 50 50 100 100 50 100 100 
TCA 50 50 50 50 50 100 100 50 100 100 
 33 
Table 6.  Effect of efflux pump inhibitors on MICs of bile salts to (A) S. aureus and 674 
(B) E. coli. 675 
 676 
 677 
A. 678 
 679 
 680 
 681 
 682 
B. 683 
 684 
NOTE.  CA, sodium cholate; DCA, sodium deoxycholate; CDCA, sodium 685 
chenodeoxycholate; GCA, sodium glycocholate; TCA, sodium taurocholate; PAβN, 686 
Phe-Arg-β-naphthylamide.  aPAβN at 20 µg/ml and Reserpine at 40 µg/ml. 687 
 688 
  689 
Bile salt S. aureus SH1000 (mM) S. aureus ∆mnhF (mM) 
 Control aPAβN aReserpine Control aPAβN aReserpine 
CA 22 2.5 10 5 2.5 2.5 
DCA 1.2 0.3 1.2 0.6 0.3 0.3 
CDCA 1.2 0.3 1.2 0.6 0.3 0.3 
GCA >200 200 >200 >200 200 >200 
TCA >200 200 >200 >200 200 >200 
Bile salt E. coli TG1 (mM) E. coli TG1 pMnhF1 (mM) 
 Control aPAβN aReserpine Control aPAβN aReserpine 
CA 30 2.5 30 90 2.5 90 
DCA 4 0.6 >4 >4 0.6 >4 
CDCA 4 0.6 >4 >4 0.6 >4 
GCA 50 10 50 100 10 100 
TCA 50 10 50 100 10 100 
 34 
Figure Legends 690 
Figure 1.  MnhF protects S. aureus against the bactericidal activity of bile salts.  691 
Viability of S. aureus SH1000 [¢],  ∆mnhF [p], ∆mnhF (pMnhF2) [u], ∆mnhF 692 
(pRMC2) [Í] treated with (A) 2 mM CA, (B) 0.25 mM DCA, and (C) 20 mM GCA.  693 
Data represents mean ± standard error of mean from three independent experiments.  694 
*P<0.01, †P>0.05. 695 
 696 
Figure 2.  Heterologous expression of MnhF in E. coli protects against the 697 
bacteriostatic effects of bile salts.  Viability of wild type E. coli TG1 and E. coli 698 
TG1 pMnhF1 cells in LB medium containing CA (10 and 20 mM), DCA (2 and 4 699 
mM) and GCA (25 and 50 mM) and then grown for overnight at 37°C. Cell counts 700 
were then determined by viable plate counting.  Data represents mean ± standard error 701 
of mean from three independent experiments.  *P<0.001 702 
 703 
Figure 3.  MnhF exports cholic acid.  (A) S. aureus SH1000 wild type [¢] and 704 
∆mnhF [p] cells were loaded with 1 µCi of 14C-cholic acid, and then diluted into a 705 
buffer containing excess of non-radiolabelled cholic acid (0.2 mM).  (B) E. coli TG1 706 
parental type (TG1) [p], E. coli TG1 expressing pBAD (TG1: pBAD) [¿] and E. 707 
coli TG1 expressing pMnhF1 (TG1: pMnhF1) [¢] cells grown overnight in LB under 708 
1% arabinose induction, were loaded with 1 µCi of 14C- cholic acid, and then diluted 709 
into a buffer containing excess of non-radiolabelled cholic acid (0.2 mM) and 1% 710 
arabinose.  At indicated times, the amount of retained 14C-cholic acid in cell pellets 711 
were determined by liquid scintillation counting.  Data represents mean ± standard 712 
error of mean of three independent experiments.  *P<0.05 713 
 714 
 35 
Figure 4.  Mutation of mnhF does not affect agr.   qRT-PCR was performed in 715 
order to quantify amounts of RNAIII in S. aureus strains during exponential and 716 
stationary phases of growth.  Data represents mean ± standard error of mean of three 717 
independent experiments.  *P>0.05. 718 
 719 
Figure 5.  MnhF is required for S. aureus survival in the human colonic model.  720 
Survival of S. aureus SH1000 [¢] and ∆mnhF [p] in the human colonic model. (A) 721 
V1, models the ascending colon, (B) V2 model the transverse colon and  (C) V3 722 
models the descending colon.  Samples were taken at inoculation (0 h) and 4, 8, 24, 723 
48, 72, and 96 hours post infection.  Results are reported as means (Log10 CFU/mL) 724 
of the data of three colonic models ± standard error of mean. *P<0.05; **P<0.001. 725 
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